116 related articles for article (PubMed ID: 2451171)
1. [In vitro induction of PHA-activated killer cells for adoptive immunotherapy of recurrent or residual malignant gliomas].
Shinoda J; Yamada H; Sakai N; Ando T; Miwa Y
Neurol Med Chir (Tokyo); 1987 Sep; 27(9):831-40. PubMed ID: 2451171
[No Abstract] [Full Text] [Related]
2. Salvage immunotherapy of malignant glioma.
Ingram M; Jacques S; Freshwater DB; Techy GB; Shelden CH; Helsper JT
Arch Surg; 1987 Dec; 122(12):1483-6. PubMed ID: 3500693
[TBL] [Abstract][Full Text] [Related]
3. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
Yoshida S; Tanaka R; Takai N; Ono K
Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
[TBL] [Abstract][Full Text] [Related]
4. [Induction of LAK cells from rat splenocytes and an anti-tumor effect of the LAK cells on the 9L-gliomas].
Imaya H
Nihon Ika Daigaku Zasshi; 1987 Oct; 54(5):479-84. PubMed ID: 3500964
[No Abstract] [Full Text] [Related]
5. [Experimental studies on the treatment of recurrent gliomas].
Yamada M; Shimizu K; Okamoto Y; Miyao Y; Matsui Y; Tsuda N; Mogami H
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1890-5. PubMed ID: 3496051
[TBL] [Abstract][Full Text] [Related]
6. [Adoptive immunotherapy in patients with malignant glioma].
Yoshida S; Takai N; Saito T; Tanaka R
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1930-2. PubMed ID: 3496052
[TBL] [Abstract][Full Text] [Related]
7. [The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma].
Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Tsuda N; Hayakawa T; Ishida N; Mogami H
No To Shinkei; 1986 Mar; 38(3):265-71. PubMed ID: 3085695
[TBL] [Abstract][Full Text] [Related]
8. Autologous natural killer cell therapy for human recurrent malignant glioma.
Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T
Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367
[TBL] [Abstract][Full Text] [Related]
9. [A new experimental approach to the specific adoptive immunotherapy for malignant gliomas].
Yamasaki T
Nihon Geka Hokan; 1983 Nov; 52(6):783-801. PubMed ID: 6331809
[No Abstract] [Full Text] [Related]
10. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral LAK cell and interleukin-2 therapy of human gliomas.
Barba D; Saris SC; Holder C; Rosenberg SA; Oldfield EH
J Neurosurg; 1989 Feb; 70(2):175-82. PubMed ID: 2643685
[TBL] [Abstract][Full Text] [Related]
12. The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2.
Rosenberg SA
Semin Oncol; 1986 Jun; 13(2):200-6. PubMed ID: 3520827
[No Abstract] [Full Text] [Related]
13. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
Yoshida S; Takai N; Ono K; Saito T; Tanaka R
No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
[TBL] [Abstract][Full Text] [Related]
14. Sterile abscesses in glioma patients treated by intraparenchymal injection of lymphokine-activated killer cells and recombinant interleukin-2: case reports.
Atkinson LL; Merchant RE; Ghatak NR; Young HF
Neurosurgery; 1989 Nov; 25(5):805-10. PubMed ID: 2586734
[TBL] [Abstract][Full Text] [Related]
15. Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA.
Jeffes EW; Beamer YB; Jacques S; Silberman RS; Vayuvegula B; Gupta S; Coss JS; Yamamoto RS; Granger GA
J Neurooncol; 1993 Feb; 15(2):141-55. PubMed ID: 8509819
[TBL] [Abstract][Full Text] [Related]
16. Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant brain tumor.
Itoh K; Sawamura Y; Hosokawa M; Kobayashi H
Radiat Med; 1988; 6(6):276-81. PubMed ID: 2854899
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.
Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
Cancer Res; 1986 Apr; 46(4 Pt 2):2101-4. PubMed ID: 3512079
[TBL] [Abstract][Full Text] [Related]
18. [Adoptive immunotherapy of malignant disease using LAK cells].
Kimoto Y; Taguchi T
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):788-96. PubMed ID: 3260466
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors.
Grimm EA
Prog Clin Biol Res; 1987; 244():185-95. PubMed ID: 3498948
[No Abstract] [Full Text] [Related]
20. Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors.
Lillehei KO; Johnson SD; McCleary EL; Mitchell DH; Schiltz PM; Kruse CA
Online J Curr Clin Trials; 1993 Dec; Doc No 111():[806 words; 5 paragraphs]. PubMed ID: 8305997
[No Abstract] [Full Text] [Related]
[Next] [New Search]
